CADL

Candel Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing oncolytic viral immunotherapies for the treatment of cancer. Headquartered in Needham, Massachusetts, Candel focuses on harnessing modified viruses that selectively infect and kill cancer cells while stimulating anti-tumor immune responses. The company's lead product candidate targets patients with non-small cell lung cancer and prostate cancer. Candel's oncolytic virus platform involves engineering herpes simplex viruses to express immunomodulatory proteins that enhance the body's immune system recognition and destruction of tumors. The company's approach combines direct tumor cell killing with immune system activation, potentially addressing both local disease and metastatic spread. Candel is conducting clinical trials evaluating its therapies as monotherapy and in combination with other cancer treatments including checkpoint inhibitors and standard chemotherapy regimens. The company has developed manufacturing capabilities and quality systems to produce viral therapies meeting regulatory requirements for clinical use. Candel's research programs explore applications across multiple cancer types where immune-based approaches may provide therapeutic benefit. The company collaborates with academic institutions and leverages expertise in virology, immunology, and oncology to advance its pipeline of investigational therapies.